See more : AZZ Inc. (AZZ) Income Statement Analysis – Financial Results
Complete financial analysis of The Oncology Institute, Inc. (TOI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of The Oncology Institute, Inc., a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- Trustco Group Holdings Limited (TTO.JO) Income Statement Analysis – Financial Results
- Global Star Acquisition, Inc. Class A Common Stock (GLST) Income Statement Analysis – Financial Results
- Imerys S.A. (NK.PA) Income Statement Analysis – Financial Results
- Ellies Holdings Limited (ELI.JO) Income Statement Analysis – Financial Results
- Jiuzi Holdings, Inc. (JZXN) Income Statement Analysis – Financial Results
The Oncology Institute, Inc. (TOI)
About The Oncology Institute, Inc.
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 324.24M | 252.48M | 203.00M | 187.51M | 155.41M | 113.16M |
| Cost of Revenue | 264.67M | 200.39M | 162.16M | 150.64M | 125.46M | 86.88M |
| Gross Profit | 59.57M | 52.09M | 40.85M | 36.88M | 29.94M | 26.28M |
| Gross Profit Ratio | 18.37% | 20.63% | 20.12% | 19.67% | 19.27% | 23.23% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 309.17K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 41.59M | 0.00 | 0.00 |
| SG&A | 113.85M | 119.69M | 83.37M | 41.90M | 29.64M | 20.39M |
| Other Expenses | 22.74M | 4.41M | 3.34M | 3.18M | 2.94M | 1.10M |
| Operating Expenses | 136.59M | 124.10M | 86.71M | 45.07M | 32.59M | 21.49M |
| Cost & Expenses | 401.26M | 324.49M | 248.86M | 195.71M | 158.05M | 108.37M |
| Interest Income | 0.00 | 4.08M | 320.00K | 254.15K | 3.38K | 0.00 |
| Interest Expense | 6.78M | 4.08M | 320.00K | 347.06K | 3.38K | 1.59K |
| Depreciation & Amortization | 5.87M | 4.41M | 3.34M | 3.18M | 2.94M | 1.10M |
| EBITDA | -70.45M | 8.40M | -7.94M | -11.29M | 307.11K | 9.08M |
| EBITDA Ratio | -21.73% | -26.57% | -20.43% | -6.02% | 0.20% | 5.27% |
| Operating Income | -77.02M | -72.01M | -45.86M | -8.20M | -2.63M | 4.79M |
| Operating Income Ratio | -23.75% | -28.52% | -22.59% | -4.37% | -1.70% | 4.23% |
| Total Other Income/Expenses | -6.09M | 81.86M | 34.26M | -6.62M | 6.63K | 71.18K |
| Income Before Tax | -83.10M | 1.90M | -11.60M | -14.81M | -2.64M | 4.86M |
| Income Before Tax Ratio | -25.63% | 0.75% | -5.71% | -7.90% | -1.70% | 4.30% |
| Income Tax Expense | -36.00K | 247.00K | -671.00K | -492.82K | 1.38M | 912.75K |
| Net Income | -83.07M | 1.66M | -10.93M | -14.32M | -4.02M | 3.95M |
| Net Income Ratio | -25.62% | 0.66% | -5.38% | -7.64% | -2.59% | 3.49% |
| EPS | -0.92 | 0.02 | -0.16 | -0.24 | -0.06 | 0.14 |
| EPS Diluted | -0.92 | 0.02 | -0.16 | -0.24 | -0.06 | 0.14 |
| Weighted Avg Shares Out | 73.75M | 72.79M | 66.23M | 59.12M | 64.45M | 28.75M |
| Weighted Avg Shares Out (Dil) | 73.75M | 80.61M | 66.23M | 59.12M | 64.45M | 28.75M |
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology Institute, Inc
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / October 30, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology Institute Inc.
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology Partners, Inc.
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Partners, Inc.. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
The Oncology Institute Joins Lantern's Cancer Care Network of Excellence
CERRITOS, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the nation, has joined Lantern's leading specialty care platform. Now, Lantern members will have access to cancer care...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology
NEW YORK, NY / ACCESSWIRE / October 16, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
Topicus.com Inc. Announces Release Date for Third Quarter Results
TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) announced today it intends to release its third quarter results on October 31, 2024.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November...
Source: https://incomestatements.info
Category: Stock Reports